Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shanghai Ginspire Biologics is the early-research and discovery services arm of Thousand Oaks Biologics in Shanghai, operating through the legal entity Shanghai Jianshun Biosciences. The company focuses on early biologics R&D and provides integrated services spanning molecular design and optimization, antibody discovery and engineering, linker-payload screening, ADC construction, developability assessment, pharmacology evaluation, early sample preparation, and CMC-enabling work. Ginspire positions itself as a platform-based CRDMO/CRO partner for complex biologics including monoclonal antibodies, bispecific antibodies, fusion proteins, and antibody-drug conjugates. The business appears service-oriented rather than a traditional therapeutics developer, though it also states it may co-develop differentiated molecules and out-license self-developed assets. Its capabilities are supported by the broader Thousand Oaks Biologics manufacturing network in Nantong and Shanghai Lingang.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shanghai Ginspire Biologics.